Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality; however, the extent to which genetic factors increase risk for PAD is largely unknown. Using electronic health record data, we performed a genomewide association study in the Million Veteran Program testing ~32 million DNA sequence variants with PAD (31,307 cases and 211,753 controls) across veterans of European, African and Hispanic ancestry. The results were replicated in an independent sample of 5,117 PAD cases and 389,291 controls from the UK Biobank. We identified 19 PAD loci, 18 of which have not been previously reported. Eleven of the 19 loci were associated with disease in three vascular beds (coronary, cerebral, peripheral), including LDLR, LPL and LPA, suggesting that therapeutic modulation of low-density lipoprotein cholesterol, the lipoprotein lipase pathway or circulating lipoprotein(a) may be efficacious for multiple atherosclerotic disease phenotypes. Conversely, four of the variants appeared to be specific for PAD, including F5 p.R506Q, highlighting the pathogenic role of thrombosis in the peripheral vascular bed and providing genetic support for Factor Xa inhibition as a therapeutic strategy for PAD. Our results highlight mechanistic similarities and differences among coronary, cerebral and peripheral atherosclerosis and provide therapeutic insights.
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Affairs (VA) Healthcare System. Approximately 10% of individuals greater than the age of 55 seeking care in the VA Healthcare System have PAD, making MVP an ideal cohort for performing a large-scale PAD genetic analysis. Leveraging the MVP resource, we sought to: (1) perform a genetic discovery analysis of PAD; (2) explore the spectrum of phenotypic consequences associated with PAD risk variants; and (3) identify genetic signals that differentiate PAD from vascular disease in other arterial beds.
We designed a two-phased GWAS (Fig. 1) . Initial discovery was performed in MVP, testing for association separately among individuals of European (white), African (black) and Hispanic ancestry. The results were then meta-analyzed across ancestral groups. For variants with suggestive associations (P < 10 −6
) with PAD, we sought replication in the UK Biobank. We then combined statistical evidence across MVP and UK Biobank and set a significance threshold of P < 5 × 10 −8 (genome-wide significance). The MVP discovery analysis was comprised of 31,307 individuals (24,009 white, 5,373 black, 1,925 Hispanic) with PAD and 211,753 PAD-free controls; their baseline characteristics are presented in Supplementary Table 1 . Participants with PAD were more likely to be older, male, prescribed statin therapy, have a history of smoking and affected with type 2 diabetes (T2D). To validate our PAD phenotype, the minimum ankle-brachial index (mABI) was extracted for 17,861 individuals with ABI measurements available in MVP. As expected, we observed a median mABI of less than 0.9 for PAD cases and approximately 1 for PAD controls across all three ethnic groups (Supplementary Table 2 and Extended Data Fig. 1 ). We further validated our MVP PAD phenotype with manual chart reviews and observed a specificity of 88% (95% confidence interval (CI) = 75.7-94.5%) and sensitivity of 100% (95% CI = 89.8-100%), commensurate with that published in the literature 7 . Through genotype imputation, we obtained 20.3 million, 32.4 million and 31.2 million DNA sequence variants for analysis in white, black and Hispanic participants, respectively (Supplementary Table 1 ). Following trans-ethnic meta-analysis in the discovery phase, a total of 554 variants at 25 loci met a genome-wide significance threshold (Extended Data Fig. 2 ). We replicated all three previously described genome-wide PAD loci with at least nominal (P < 0.05) significance (Supplementary Table 3 ). A total of 1,276 variants demonstrated association P < 10 -6 in the MVP discovery analysis. Of those, 552 were also available for independent testing in the UK Biobank (5,117 PAD cases, 389,291 controls) and were taken forward for replication. Following replication, 19 loci exceeded genome-wide significance (P < 5 × 10 −8
, Table 1 and Supplementary  Table 4 ). Of the 19 PAD loci, 15 were directionally consistent across whites, blacks and Hispanics in MVP, 8 demonstrated at least nominal significance in blacks and 3 in Hispanics (Supplementary Table 5 ); 18 of the loci have not been previously reported (Extended Data Fig. 3 ).
The LPA variant rs118039278 was the top association result (6.4% frequency for the A allele; odds ratio (OR) = 1.25; 95% CI: 1.22-1.30; P = 1.57 × 10
−43
). Of the six signals from MVP that did not replicate in the UK Biobank, two were rare variants that were not available in UK Biobank following quality control (European minor allele frequency (MAF) < 0.005), and the remaining four did not meet the pre-specified P < 0.05 for independent replication (Supplementary Table 6 ). All three previously reported suggestive (5.0 × 10 −8 < P < 0.05) PAD associations at the SH2B3/PTPN11 (ref. 8 ), HDAC9 (ref. 4 ) and CHRNA3 (ref. 9 ) loci were observed at genome-wide significance.
We next studied whether DNA sequence variants were associated with PAD severity as determined by mABI. We performed a GWAS of mABI as a continuous trait for 13,382 European, 3, 284 African and 998 Hispanic ancestry individuals in MVP, restricted to those with an ABI <1.4 as previously described 3 . Baseline characteristics for these individuals are depicted in Supplementary Table 7 .
Following trans-ethnic meta-analysis, only the known 9p21-ABI association 3 passed the genome-wide significance threshold (rs1333045, 46 .8% frequency for the T allele; β = 0.064; 95% CI: 0.042-0.086; P = 8.3 × 10
−9
). However, we observed that 6 of the 19 PAD risk variants identified in our PAD case/control analysis were associated with reduced mABI at nominal significance (P < 0.05, Supplementary Table 8) . Notably, the mABI GWAS lead 9p21 variant (rs1333045) was different than the lead variant identified in the PAD case-control analysis at this locus (rs1537372).
Understanding the full spectrum of phenotypic consequences of a given DNA sequence variant can help to identify the mechanism by which a variant or gene leads to disease. Termed a phenomewide association study (PheWAS), this approach examines the association of a risk variant across a range of phenotypes 10, 11 . Using a median of 65 distinct EHR-derived diagnosis codes (International Calssification of Disease 9th and 10th revisions (ICD-9/10)) per participant, we tested each of the 19 PAD lead risk variants across 1,101 disease phenotypes. We found that several of the newly identified DNA sequence variants correlated with a range of known risk factors for PAD ( Fig. 2 and Supplementary Table 9 ). For example, rs7903146 within TCF7L2 is one of the strongest known genetic predictors of T2D 12 and associated with T2D in our PheWAS. The PAD association for rs7903146 was significantly reduced when controlling for T2D in the regression model, suggesting this variant confers PAD risk through its effect on T2D (Extended Data  Fig. 4 ). The Factor V Leiden variant (F5 p.R506Q) demonstrated a known association with venous thromboembolism 13 . We found four PheWAS associations with hypercholesterolemia and one with hypertriglyceridemia. These loci have previously associated with either low-density lipoprotein (LDL) cholesterol (LDLR, ABO, SORT1 and LPA) or triglycerides (LPL) 14 , known causal paths to atherosclerosis. rs10851907 in CHRNA3 (encoding cholinergic receptor nicotinic alpha-3) demonstrated an association with chronic obstructive pulmonary disease. This DNA sequence variant is strongly correlated (R 2 = 0.73) with variants previously shown to predict nicotine dependence 9 and appears to drive PAD risk entirely through its effect in smokers (Extended Data Fig. 5 ). rs3130968 The association of DNA sequence variants with PAD was tested separately in three mutually exclusive ancestry groups and the results combined using an inverse-variance weighted fixed-effects meta-analysis in the discovery phase. Variants with suggestive association (two-sided logistic regression P < 10
) were then brought forward for independent replication in the UK Biobank.
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near the HLA-B gene was associated with a number of autoimmune diseases including celiac disease, Graves' disease, systemic lupus erythematosus and type 1 diabetes 15 . In total, we identified 158 statistically significant (P < 5.0 × 10 −8
) PheWAS associations across the 19 genetic variants implicating many known PAD risk factors based on the traits they relate to, including lipids, T2D, smoking, thrombosis and hypertension 16 (Extended Data Fig. 6 ). We supplemented our MVP PheWAS with data from PhenoScanner V2 (ref. 17 ), an online resource of association statistics from previously conducted GWASs and UK Biobank. In total, we identified 443 additional PheWAS associations from the PhenoScanner database at P < 5 × 10 −8 (Supplementary Table 10 ). We subsequently prioritized likely candidate causal PAD risk genes by aggregating evidence from (1) prior genetic, clinical, or functional studies, (2) our PheWAS results, (3) cis-expression quantitaive trait locus (eQTL) from the Genotype-Tissue Expression Project (GTEx) V7 data set 18 , (4) recently published protein quantitative trait locus (pQTL) data derived from the human plasma of 3,301 participants of the INTERVAL study 19, 20 and (5) results from a transcriptome-wide association study 21 (TWAS) using RNA-seq data from post-mortem tibial artery tissue (388 individuals) and MVP European PAD summary statistics. This analysis revealed several candidate causal genes including F5, LPA, SORT1, LPL and LDLR (Supplementary Tables 11 and 12) .
We next sought to understand how DNA sequence variants might differ in their contribution to vascular disease risk in the peripheral, coronary and cerebral arterial territories. Analysis of shared heritability provides a mechanism that describes the relationship of common variant risk across phenotypes 22, 23 . Using linkage disequilibrium score regression 23 , we examined the genetic correlation (r g ) between PAD and both coronary artery disease (CAD) and large artery stroke (LAS). We used summary statistics from the European MVP PAD analysis, along with summary data of 60,801 coronary disease cases and 123,504 disease-free controls from the CARDIoGRAMplusC4D consortium 24 , and 6,688 LAS cases and 454,450 controls from the 2018 MEGASTROKE analysis 25 . We noted a stronger positive correlation between PAD and LAS (r g = 0.88, P = 5.5 × 10 ) than for PAD and CAD (r g = 0.62, P = 1.57 × 10
−43
). Based on these findings, we explored the differential effects of individual genetic variants on PAD, LAS and CAD. 
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The 19 lead PAD risk variants identified in our GWAS analysis were tested for their effects on CAD and LAS in white MVP participants. The results were then combined with summary statistics from the CARDIoGRAMplusC4D or MEGASTROKE studies, respectively. We observed that 14 PAD risk variants demonstrated at least nominal association (P < 0.05) with CAD, and 12 with LAS (Supplementary Tables 13-16 ). In a sensitivity analysis, the PAD effect estimates at the SORT1, LPA, 9p21 and LDLR loci were attenuated, suggesting that some of the PAD risk may be driven by co-morbidity or shared causal pathways when accounting for the concomitant CAD and LAS diagnoses (Supplementary Tables  17-19 ). The COL4A1 locus, previously associated with CAD 24 and small vessel disease of the brain 26 , was found to be associated with PAD and CAD but not with LAS in our analysis. Data from the MEGASTROKE study demonstrate evidence of association with small artery stroke (P = 1.4 × 10 −4 ) for this variant, suggesting it may be acting differently in the cerebral bed.
Common mechanisms emerged for the 11 PAD risk variants demonstrating significant association in all three (coronary, cerebral and peripheral) vascular beds including lipids (LDLR, LPA, LPL and SORT1), hypertension (PTPN11), and diabetes (TCF7L2). Conversely, variants in the RP11-359M6.3, HLA-B, CHRNA3, and F5 loci were uniquely associated with PAD, implying that smoking and thrombosis may play a greater role in PAD than disease in other arterial territories (Extended Data Figs. 7 and 8).
The novel PAD risk variant Factor V Leiden (F5 p.R506Q) is the most common cause of inherited thrombophilia 27 , as the proteinaltering consequence of the variant results in a resistance to proteolysis by activated protein C
28
. In a combined analysis of 111,216 coronary disease cases and 248,081 controls from MVP (9,388 Factor V Leiden carriers) and CARDIoGRAMplusC4D, we observed no evidence of an association between F5 p.R506Q and CAD (OR = 1.01; 95% CI: 0.97-1.05; P = 0.72, Fig. 3a) . Similarly, for 7,393 LAS cases and 628,737 controls from MVP and MEGASTROKE, we observed no evidence of an association between F5 p.R506Q and LAS (OR = 1.03; 95% CI: 0.89-1.20; P = 0.65, Fig. 3b ). In contrast, F5 p.R506Q was associated with a 20% increased risk of PAD in individuals of European ancestry in MVP (OR = 1.20; 95% CI: 1.14-1.27; P = 8.81 × 10
, Fig. 3c ). To better understand Factor V Leiden's relationship with PAD, we tested its association with increasingly severe disease manifestations, including claudication, rest pain, tissue loss and major amputation. In total, we identified 5,797 individuals with intermittent claudication, 1,000 with rest pain, 1,773 with evidence of tissue loss and 438 who had undergone a major amputation among white MVP participants (Supplementary Table 2 ). We observed significant associations for the Factor V Leiden mutation with each subtype of PAD (Fig. 3c) . Interestingly, the variant's effect estimate increased as PAD severity increased, with carriers having a 62% increased risk of undergoing a PAD-related major amputation (OR = 1.62; 95% CI: 1.16-2.26; P = 0.005).
Recent evidence has linked tobacco use to an increased risk for thrombotic sequelae 29, 30 . We hypothesized that there may be an interaction between smoking and F5 p.R506Q carrier status on PAD risk. We observed that the presence of F5 p.R506Q had greater effect on PAD among current smokers (OR = 1.40; 95% CI: 1.25-1.58; P = 1. Letters NATURE MEDiCiNE P = 0.0059, Fig. 3d ). These findings may be secondary to a synergistic effect of active tobacco consumption on the hypercoagulability induced by F5 p.R506Q. Our study should be interpreted within the context of its limitations. First, our PAD phenotype is based on EHR data and may result in misclassification of case status. Such misclassification should, however, reduce statistical power for discovery and on average bias results toward the null. Second, the VA Healthcare System population is overwhelmingly male, and although over 20,000 women were included in our analysis, our ability to detect sexspecific genetic associations was limited. Third, our mABI values were extracted from the EHR using natural language processing techniques from unstructured data, and these values are subject to greater misclassification than those ascertained from a prospective cohort study. Lastly, while we maximized the number of participants in our PheWAS analysis, it may still have been underpowered to detect association with certain diseases.
These findings permit several conclusions. First, a multi-ethnic, VA Healthcare System-based biobank offers potential to aid genetic discovery for understudied atherosclerosis syndromes. Previously published genome-wide PAD efforts have been limited by small sample sizes 4 , and in our study we leverage the high prevalence of atherosclerotic disease within the VA Healthcare System 31 to increase the number of PAD cases analyzed by 10-fold. The extensive VA EHR-including a median of 10.0 years of follow-up per participant, >21 million prevalent diagnosis codes and 261,835 ABI measurements-enabled us to identify and validate PAD cases, more deeply phenotype patients with sequelae of severe PAD, and highlight causal mechanisms of PAD risk variants through PheWAS. Our findings provide genetic evidence that therapies targeting atherosclerotic risk factors are likely to mitigate the rising incidence of PAD 32 . Second, our results highlight mechanistic symmetries and differences between coronary, cerebral and peripheral vascular disease that provide therapeutic insights. We identified 11 genetic loci common to CAD, LAS and PAD, including the low-density lipoprotein receptor (LDLR), lipoprotein lipase (LPL) and lipoprotein(a) (LPA). These data suggest that therapeutic modulation of LDL cholesterol, the LPL pathway or circulating lipoprotein (a) 33-36 may all be efficacious for atherosclerosis in multiple vascular beds, including PAD. Conversely, the identification of four genetic signals specific to PAD imply that certain therapies may produce a substantially greater therapeutic benefit in one vascular bed over another and rejuvenate hypotheses regarding the role of autoimmune disease in atherosclerosis 37 . Further genetic analysis with greater sample sizes may reveal additional therapeutic targets that uniquely benefit PAD patients.
Third, our findings lend human genetic support to targeting the coagulation cascade as a therapeutic strategy for PAD. In our study, carriers of the thrombophilic Factor V Leiden mutation demonstrated a significantly increased risk of severe PAD including rest pain, tissue loss and major amputation. Recent results from the COMPASS trial are consistent with our genetic findings, having demonstrated that the addition of low-dose rivaroxaban to aspirin prevented major adverse limb events, including major amputation 38 . Rivaroxaban selectively inhibits factor Xa and in the COMPASS trial was used at levels well below the antithrombotic dose, suggesting that there may be something specific about direct factor Xa inhibition that prevents adverse limb outcomes. Studies such as ours provide additional mechanistic support to this hypothesis, given the intimate relationship between factors Xa and V in the thrombotic cascade. Factor Xa activates factor V and factor Va is a prerequisite for factor Xa to convert prothrombin to thrombin, suggesting a potentially important mechanism of limb atherogenesis.
In summary, we identified 18 novel genomic loci associated with PAD risk, explored the phenotypic consequences of PAD risk variants through PheWAS, and identified four risk variants that appear to drive vascular disease more specifically in the peripheral vasculature, including the Factor V Leiden variant. These results are demonstrative of how large biobanks that couple genetic variation with dense EHR data can be leveraged for biological insights that can inform clinical care.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0492-5. ), we sought replication of our findings in the UK Biobank ( Fig. 1 and Extended Data Fig. 9 ). In the UK Biobank, individuals aged 45 to 69 years old were recruited from across the United Kingdom for participation. In this study, we identified 5,117 PAD cases and 389,291 controls of European ancestry. MVP received ethical/study protocol approval by the VA Central Institutional Review Board, the analysis in UK Biobank was approved by a local Institutional Review Board at Partners Healthcare (protocol 2013P001840) and informed consent was obtained for all participants. Additional information regarding experimental design and participants are provided in the Nature Research Reporting Summary.
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Genetic data and quality control. DNA extracted from whole blood was genotyped in MVP using a customized Affymetrix Axiom biobank array, the MVP 1.0 Genotyping Array. Veterans (former US military personnel) of three mutually exclusive ethnic groups were identified for analysis: (1) non-Hispanic whites (European ancestry), (2) non-Hispanic blacks (African ancestry) and (3) self-identified Hispanics. Before imputation, variants that were poorly called or that deviated from their expected allele frequency based on reference data from the 1000 Genomes Project 39 were excluded. After pre-phasing using EAGLE v.2 (ref. 40 ), genotypes from the 1000 Genomes Project 39 phase 3, v.5 reference panel were imputed into MVP participants via Minimac3 software 41 . Ethnicity-specific principal component analysis was performed using EIGENSOFT v.6 software 42 . Participants were then divided into three mutually exclusive ethnic groups based on self-identified race/ethnicity and admixture analysis using the ADMIXTURE v.1.3 software 43 : (1) non-Hispanic whites (self-identified as 'non-Hispanic, ' 'white, ' and >80% genetic European ancestry), (2) non-Hispanic blacks (self-identified as 'non-Hispanic, ' 'black, ' and >50% genetic African ancestry) and (3) Hispanics (self-identified only). In total, 312,571 white, black and Hispanic MVP participants passed our sample-level quality control.
In MVP, sample and variant quality control was performed as previously described 44 . In brief, duplicate samples, samples with more heterozygosity than expected, an excess (>2.5%) of missing genotype calls, or discordance between genetically inferred sex and phenotypic gender were excluded. In addition, one individual from each pair of related individuals (kinship > 0.0884 as measured by KING 45 v.2.0 software) were removed. Following imputation, variant level quality control was performed using the EasyQC R package 46 (www.R-project.org), and exclusion metrics included: ancestry-specific Hardy-Weinberg equilibrium 47 
, posterior call probability < 0.9, imputation quality <0.3 (MAF < 0.0003), call rate <97.5% for common variants (MAF > 1%) and call rate <99% for rare variants (MAF < 1%). Variants were also excluded if they deviated >10% from their expected allele frequency based on reference data from the 1000 Genomes Project 39 . Following variant level quality control, we obtained 20.3 million, 32.4 million and 31.2 million DNA sequence variants for analysis in white, black and Hispanic participants, respectively.
In the UK Biobank, analysis was performed separately in white individuals after genotyping using either the UK BiLEVE or UK Biobank Axiom Arrays. Approximately 500,000 individuals were genotyped and subsequently imputed to the Haplotype Reference Consortium (HRC). Details of these procedures are described elsewhere 48 . We performed genome-wide association testing for PAD in the UK Biobank using all variants in the HRC reference with MAF > 0.5% and imputation quality INFO > 0.3. To avoid potential population stratification, only European-ancestry samples were included in the analysis. This subset was selected based on self-reported white ethnicity that was subsequently confirmed using genetic principal components analysis. Outliers within the self-reported white samples in the first six principal components of ancestry were detected and subsequently removed using the R package aberrant 49 . In addition, individuals with sex chromosome aneuploidy (neither XX or XY), discordant self-reported and genetic sex, or excessive heterozygosity or missingness, as defined centrally by the UK Biobank were removed. Finally, one individual from each pair of seconddegree or closer relatives (kinship > 0.0884) was removed, selectively retaining PAD cases when possible.
PAD definitions.
From the 312,571 multi-ethnic participants passing quality control in MVP, individuals were defined as having PAD based on possessing at least two of the ICD-9/10 codes/Current Procedural Terminology (CPT) codes outlined in Supplementary Table 20 in their EHR, or having one code and at least two visits to a vascular surgeon within a 14 month period 50 . Individuals were defined as controls if they had zero diagnosis/procedure codes suggesting a diagnosis of PAD (including those in Supplementary Table 21 ) and their EHR reflected two or more separate encounters in the VA Healthcare System in each of the 2 years before enrollment in MVP. Manual chart review was performed by two trained nurse chart abstractors with a vascular surgeon reviewing discordant cases; the results of chart review for 50 cases and 50 controls otherwise representative of the overall cohort were used for determining the sensitivity and specificity of the phenotyping algorithm. In the UK Biobank, individuals were defined as having PAD based on possession of at least one of the self-reported illness codes, OPCS procedure codes or ICD codes in Supplementary Table 22 in their EHR. All other individuals were defined as controls. In both cohorts, individuals were not excluded from the PAD control group if they possessed diagnosis codes for either CAD or LAS.
Assignment of smoking status in MVP.
Smoking status was derived from an algorithm that utilized diagnosis codes, medications, clinic identifier codes and smoking-related health factors from the VA EHR to classify individuals as never, former or current smokers from American Heart Association abstract A18809 51 .
Ankle-brachial index extraction and GWAS quality control. A natural language processing algorithm was used to extract ABI data from the EHR in MVP. Resultant values were manually inspected for accuracy. In total, 261,835 ABI measurements across 17,861 individuals were available for analysis. We selected each individual's minimum ABI (mABI) for association analysis to minimize confounding from treatment or revascularization.
We performed a GWAS of mABI in 13,382 European, 3,284 African and 998 Hispanic ancestry MVP participants after restricting to those with value <1.4 as previously described 3 . Sample and variant quality controls were performed in identical manner to the MVP PAD case/control analysis, with the exception of excluding variants with MAF < 0.01 given the smaller sample size. In total, we obtained 9.2 million, 15.6 million and 10.8 million DNA sequence variants for analysis in white, black and Hispanic participants, respectively.
PheWAS of PAD risk variants.
Understanding the full spectrum of phenotypic consequences of a given DNA sequence variant may shed light on the mechanism by which a variant/gene leads to disease. For lead PAD risk variants identified in our primary analysis, we performed a PheWAS of 1,101 distinct diseases in MVP leveraging the full catalog of EHR ICD-9 diagnosis codes in 176,913 white veterans passing PheWAS quality control using the R package PheWAS 52 and its associated disease definitions with the exception of CAD defined as previously described 35 . Diseases were required to have a prevalence of >0.2% (~300 cases) to be included in the PheWAS analysis. Lead PAD risk DNA sequence variants were tested using logistic regression adjusting for age, sex and five principal components under the assumption of additive effects.
We supplemented our MVP PheWAS with data from PhenoScanner V2 (ref. 17 ), an online resource of association statistics from previously conducted GWASs and UK Biobank and used a genome-wide significant P value threshold (two-sided P < 5 × 10
−8
). PhenoScanner data sources are outlined in Supplementary Table 23. eQTL/pQTL associations and PAD transcriptome-wide association study. To identify loci that might influence gene expression, we used previously published eQTL mapping data from the Genotype-Tissue Expression (GTEx) Consortium Project across 44 tissues 18 . We queried the 19 PAD risk variants identified in our study for overlap with genome-wide significant variant-gene pairs from the GTEx portal. Similarly, to identify loci that might influence protein concentrations in plasma, we used published pQTL data generated from an aptamer-based multiplex protein assay to quantify 3,622 plasma proteins in 3,301 healthy participants from the INTERVAL study 19, 20 . We queried the 19 lead PAD risk variants identified in our study for overlap with genome-wide significant variant-protein pairs.
We then performed a TWAS using summary statistics from the European MVP PAD analysis and gene-expression reference panels of tibial artery from GTEx V7 in 388 independent samples, as previously described 21 . In brief, for a given gene, variant-expression weights in the 1-mB cis locus were first computed with the BSLMM 53 , which "models effects on expression as a mixture of normal distributions to account for the sparse expression architecture. Given weights w, lipid Z scores Z, and variant-correlation (LD) matrix D; the association between predicted expression and lipids (i.e., the TWAS statistic) was estimated as Z TWAS = w'Z/(w'Dw) 1/2 " (details in ref. 21 ). We computed TWAS statistics by using either the variants genotyped in each expression reference panel or imputed HapMap3 variants. To account for multiple hypotheses, we applied a Bonferroni corrected two-sided P < 6.2 × 10 −6 = (0.05/8089 genes).
Shared heritability within PAD, CAD and LAS.
To better understand how common genetic variation influences risk for atherosclerosis in multiple vascular beds, we used linkage disequilibrium score regression 23 to calculate the genetic correlation between PAD-CAD and PAD-LAS. Summary statistics from the European MVP PAD GWAS, the CARDIoGRAMplusC4D CAD GWAS 24 (predominantly European) and the transancestral LAS MEGASTROKE GWAS meta-analysis (greater than two-thirds European) 25 were used for this analysis. Of note, we used the transancestral meta-analysis statistics from MEGASTROKE because the sample size of the European-ancestry only analysis lacked sufficient power for estimation of genetic correlation.
PAD associations independent of CAD and LAS. DNA sequence variants might differ in contribution to risk for atherosclerosis in the peripheral, coronary and
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combined results with summary statistics from the CARDIoGRAMplusC4D and MEGASTROKE consortium studies, respectively. We performed a sensitivity analysis for variants demonstrating at least a nominally significant association with either CAD and/or LAS, by re-testing their association with PAD after including CAD or LAS status as a covariate in the association model. We also re-tested their association including both CAD and LAS as covariates in a single model. Variants associated with PAD, CAD and LAS individually, and that remained associated with PAD after adjustment for CAD/LAS suggest the presence of a common mechanism or pathway leading to the development of atherosclerosis in multiple arterial beds. Conversely, associations that are present uniquely with PAD suggest a mechanism specific to the peripheral vascular bed.
MVP CAD definition and analysis. CAD was defined based on ICD-9/10 and CPT codes using the method described by Dewey and colleagues 35 . CAD cases were defined as individuals who, based on ICD-9, ICD-10 and CPT codes had an inpatient admission with a primary diagnosis of CAD, a combination of CAD associated inpatient or outpatient encounters on two or more distinct days noted in the longitudinal VA EHR or fee-for-service data, or a coronary revascularization at the time of analysis (Supplementary Table 24 ). We identified 50,415 CAD cases and 124,577 controls available for analysis among 174,992 white MVP participants. Genotyped and imputed DNA sequence variants were tested for association with CAD through logistic regression adjusting for age, sex and five principal components of ancestry. Results were then combined with publicly available summary data of 60,801 CAD case patients and 123,504 disease-free controls in the CARDIoGRAMplusC4D consortium study 24 using an inverse-variance weighted fixed-effects method. For variants with a high amount of heterogeneity across the two studies (I 2 statistic >75%, for example, rs4842266), results were combined using a random effects method.
MVP LAS adjusted analysis and definition. LAS was defined based on the groupings proposed by Denny et al. 52 and the phecode 433.11, occlusion of the cerebral arteries with cerebral infarction, which is defined as the occurrence of the any of following ICD-9-CM codes on two or more distinct dates: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91. We identified 705 LAS cases and 174,287 controls available for analysis among 174,992 white MVP participants. Genotyped and imputed DNA sequence variants were tested for association with LAS through logistic regression adjusting for age, sex and five principal components of ancestry. Results were then combined with publicly available summary data of the transancestral LAS MEGASTROKE meta-analysis 25 of 6,688 LAS cases and 454,450 controls using an inverse-variance weighted fixed-effects method.
T2D definition for TCF7L2 adjusted analysis. To better understand how the TCF7L2 locus affects PAD risk, rs7903146 was re-tested for association with PAD after adjusting for T2D status in the 174,992 white MVP participants. T2D was defined based on the groupings proposed by Denny et al. 52 , which identified 78,431 MVP participants affected with T2D (58,621 white and 5,273 black). We first tested the association of rs7903146 in MVP with T2D through logistic regression adjusting for age, sex and five principal components of ancestry separately in whites and blacks. We then re-tested for association with PAD through logistic regression adjusting for age, sex, T2D and five principal components of ancestry. We report logistic regression two-sided P values.
Factor V Leiden genotypes and risk of vascular disease. One of the variants most strongly associated with PAD in the discovery analysis was the Factor V Leiden mutation, the most common cause of inherited thrombophilia 27 . The variant's protein-altering consequence (F5 p.R506Q) results in a resistance to proteolysis by activated protein C and a hypercoaguable state 28 . We sought to better understand Factor V Leiden's relationship with atherosclerosis by testing its association with CAD, LAS and increasingly severe presentations of PAD. Individuals were defined as having claudication, rest pain, tissue loss, or major amputation if they met our EHR-based definition for PAD and possessed at least one diagnosis code depicted in Supplementary Table 25 . If an individual possessed diagnosis codes for more than one severe PAD presentation (for example, claudication and rest pain), the most severe PAD classification was selected. We then evaluated for evidence of an interaction between smoking and F5 p.R506Q carrier status.
Statistical analysis.
In our primary analysis, genotyped and imputed DNA sequence variants were tested for association with PAD using logistic regression adjusting for age, sex and five principal components of ancestry assuming an additive model using the SNPTEST v.2.5.4 (mathgen.stats.ox.ac.uk/genetics_ software/snptest/snptest.html) statistical software program. In our MVP discovery analysis, we performed association analyses separately for each ethnic group (whites, blacks and Hispanics) and then meta-analyzed using an inverse-variance weighted fixed-effects method implemented in the METAL software program 54 . We excluded variants with a high amount of heterogeneity (I 2 statistic >75%) across the three ancestries. In addition, we required that variants be observed in at least two ethnic groups.
For variants with suggestive PAD associations (P < 10
) we sought replication of our findings in UK Biobank. Association testing was performed in 5,117 PAD cases and 389,291 controls using a logistic regression model adjusted for age at baseline, sex, genotyping array and the first 10 principal components of ancestry. All testing was performed in PLINK v.2 (https://www.cog-genomics.org/ plink/2.0/). We defined significant novel PAD associations as those that were at least nominally significant in replication (P < 0.05), were directionally consistent in both cohorts, and had an overall P < 5 × 10 −8 (genome-wide significance) in the discovery and replication cohorts combined. Novel loci were defined as being greater than 500,000 base pairs away from a known PAD genome-wide associated lead variant. Additionally, linkage disequilibrium information from the 1000 Genomes Project 39 was used to determine independent variants where a locus extended beyond 500,000 base pairs. All logistic regression values of P were twosided.
In our ABI GWAS, DNA sequence variants were tested with linear regression using an untransformed mABI value adjusting for age, sex and five principal components of ancestry. We performed association analyses separately for each ethnic group and then meta-analyzed the results using an inverse-variance weighted fixed-effects method. A P < 5.0 × 10 −8 was used to declare genome-wide significance for the continuous mABI trait.
In our PheWAS analysis, DNA sequence variants were tested using logistic regression adjusting for sex, and five principal components of ancestry against disease-free controls and declared to be significantly associated with the disease if they met a P < 5.0 × 10 −8
. In our CAD/LAS sensitivity analysis, risk variants identified in the primary analysis were tested for association with CAD/LAS in white MVP participants and combined with either (1) publicly available summary data of 60,801 CAD case patients and 123,504 disease-free controls in the CARDIoGRAMplusC4D consortium study 24 or (2) with the transancestral LAS MEGASTROKE meta-analysis 25 of 6,688 LAS cases and 454,450 controls using an inverse-variance weighted fixed-effects method. Variants demonstrating at least nominal (P < 0.05) significance with CAD/LAS were then re-tested with PAD after adjusting for CAD or LAS status in MVP. Variants were declared to still be associated with PAD if they demonstrated a reduction in association signal when adjusting for CAD/LAS status but P PAD remained <0.05. All logistic regression values of P were two-sided.
In our Factor V Leiden analysis, the Leiden variant was tested for association with each subtype of PAD (intermittent claudication, rest pain, tissue loss, major amputation), as compared to PAD free controls, through logistic regression adjusting for sex, and five principal components of ancestry. Lastly, we evaluated for evidence of a Factor V Leiden-smoking interaction by stratifying MVP participants into current smokers and former/never smokers and performed a Cochran's Q test for interaction. In our Factor V Leiden analysis, we set a Bonferroni-adjusted level of significance of P = 0.05 ÷ 7 tests = 0.007. All values of P in the Factor V Leiden analysis were two-sided.
To determine the specificity and sensitivity values of our PAD phenotype, we performed a manual chart review and calculated the resultant values using the R v.3.2.0 software (Supplementary Table 26 ). Sensitivity refers to the ratio of (true positives)/(true positives + false negatives) and specificity the ratio of (true negatives)/(true negatives + false positives).
Natural language processing algorithm for ABI. ABI values measured for patients in the VA Healthcare System are not recorded in a structured format in the EHR. Instead, the values can be found in clinical reports in narrative or semistructured format (Extended Data Fig. 10 ). In order to make these ABI values available for the PAD phenotype definition, we developed a natural language processing system to identify instances of ABI values recorded within clinical notes. The system was developed in several stages and the results of an initial iteration of the system development were reported previously 55 . To develop a rule-based natural language processing system that could scale to process the 6.5 million documents associated with the 31,307 patients in the discovery analysis cohort, we utilized the Leo framework 56 , which builds on the Unstructured Information Management Architecture -Asynchronous Scaleout 57 . The system achieved 96.4% precision as validated on 1,000 manually labeled clinical notes. A sensitivity analysis showed 89.8% recall on an instance level across 200 documents selected from the same day as a PAD diagnosis code.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The full summary level association data from the MVP transancestry PAD meta-analysis from this report are available through dbGAP, accession code phs001672.v2.p1. Additional data that support the findings of this study are available on request from the corresponding author (S.M.D.); these data are not publicly available due to US Government and Department of Veteran's Affairs restrictions relating to participant privacy and consent. Data contributed by CARDIoGRAMplusC4D investigators are available online (http://www. CARDIOGRAMPLUSC4D.org/). Data on LAD have been contributed by the MEGASTROKE investigators and are available online (http://www.megastroke.org/).
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Data collection
Phenotypic data was collected from the electronic health record and genetic data using the Million Veteran Program (MVP) Axiom array.
Data analysis
Imputation was performed using MiniMac3/EAGLE v2, and data was collected and cleaned using the EasyQC package, SNPTESTv2.5.4, EIGENSOFT v6, METAL (released 2011), and KING 2.0 software programs as outlined in the online methods. Clear code for analysis is available at their associated website (see text). Additional analyses were performed in R-3.2.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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